- Home
- LOCL vs APRE Comparison
LOCL vs APRE Comparison
Compare LOCL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCL
- APRE
- Stock Information
- Founded
- LOCL 2021
- APRE 2006
- Country
- LOCL United States
- APRE United States
- Employees
- LOCL N/A
- APRE N/A
- Industry
- LOCL Farming/Seeds/Milling
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOCL Consumer Staples
- APRE Health Care
- Exchange
- LOCL Nasdaq
- APRE Nasdaq
- Market Cap
- LOCL 15.0M
- APRE 15.8M
- IPO Year
- LOCL N/A
- APRE 2019
- Fundamental
- Price
- LOCL $2.03
- APRE $3.05
- Analyst Decision
- LOCL
- APRE Strong Buy
- Analyst Count
- LOCL 0
- APRE 2
- Target Price
- LOCL N/A
- APRE $15.50
- AVG Volume (30 Days)
- LOCL 33.7K
- APRE 22.6K
- Earning Date
- LOCL 11-14-2024
- APRE 11-07-2024
- Dividend Yield
- LOCL N/A
- APRE N/A
- EPS Growth
- LOCL N/A
- APRE N/A
- EPS
- LOCL N/A
- APRE N/A
- Revenue
- LOCL $34,934,000.00
- APRE $1,310,839.00
- Revenue This Year
- LOCL $44.36
- APRE $134.21
- Revenue Next Year
- LOCL $107.44
- APRE N/A
- P/E Ratio
- LOCL N/A
- APRE N/A
- Revenue Growth
- LOCL 27.83
- APRE 130.31
- 52 Week Low
- LOCL $1.18
- APRE $2.15
- 52 Week High
- LOCL $3.33
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- LOCL 55.31
- APRE 43.20
- Support Level
- LOCL $1.18
- APRE $3.02
- Resistance Level
- LOCL $2.50
- APRE $3.39
- Average True Range (ATR)
- LOCL 0.29
- APRE 0.30
- MACD
- LOCL 0.09
- APRE -0.01
- Stochastic Oscillator
- LOCL 64.39
- APRE 3.85
About LOCL Local Bounti Corporation
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.